2023 Guidance and Q3 Earnings

Glossary ADC AE Antibody drug conjugate Adverse event EGPA Eosinophilic granulomatosis with polyangiitis NSCLC Non-small cell lung cancer FVC Forced vital capacity OMV Outer membrane vesicle AESI Adverse event of special interest GC Urogenital gonorrhea ORR Overall response rate AUC Area under curve GMMA Generalised Modules for Membrane Antigens OS Overall surival BCMA B-cell maturation antigen GSI Gamma secretase inhibitor PBC Primary biliry cholangitis BICR Blinded Independent Central Review HA Healthy adults PFS BRCA Breast cancer HBV Hepatitis B virus PFS2 CAE Corneal adverse events HES Hypereosinophilic syndrome PK CBR Clinical benefit rate Hgb Hemoglobin PMF CCR Complete clinical response hSBA Human serum bactericidal assay CKD Chronic kidney disease HZ Herpes zoster RL CfB Change from baseline IC Immunocompromised RRMM CMV Cytomegalovirus ICR Independent central review RSV CN China iNTS Invasive non-typhoidal salmonella SAD Progression-free survival Time to second disease progression or death Pharmacokinetic Primary myelofibrosis Post-PV/ET MF Post-essential thrombocythemia myelofibrosis Repeat dose level Relapsed/refractory multiple myeloma Respiratory syncytial virus Single ascending dose COPD Chronic obstructive pulmonary disease ITT Intention-to-treat SAE Serious adverse event CP Cholestatic pruritus JP Japan siRNA Small interfering RNA CRR Complete response rate LLOQ Lower limit of quantitation SoC Standard of care CRSWNP Chronic rhinosinusitis with nasal polyps LRTS Lower respiratory tract symptoms SSC-ILD CUTI Complicated urinary tract infection MAD Multiple ascending dose TOC Systemic sclerosis associated interstitial lung disease Test of cure CV Cardiovascular MAE Medical attended events TTBR Time to best response DDI Drug-drug interaction MAPS Mulitple Antigen Presenting System TTD Time to treatment discontinuation DFS Disease-freee survival MM Multiple myeloma TTP Time to tumour progression DL Dose level MMR Measles, mumps and rubella TTR Time to treatment response DLT Dose-limiting toxicity MMRV Measles, mumps, rubella and varicella UTI dMMR Deficient mismatch repair MRD Multiple rising dose uUTI DoR Duration of response MSI-H Microsatellite instability high VGPR DPNP Diabetic peripheral neuropathic pain NASH Nonalcoholic steatohepatitis VSP EASI Eczema Area and Severity Index NRS Numeric Rating Scale YoA Urinary tract infection Uncomplicated urinary tract infection Very good partial remission Vital sign parameters Years of age GSK 40 40

View entire presentation